Arrowhead Pharmaceuticals Pulmonary R&D Day
About The Event
Join us for the Arrowhead Pulmonary R&D Day, featuring presentations from Key Opinion Leaders (KOLs) Mario Castro, M.D., MPH (University of Kansas Medical Center) and Matthias Salathe, M.D. (University of Kansas Medical Center) who will discuss the current treatment landscape and unmet medical need in treating patients with muco-obstructive and inflammatory pulmonary diseases.
The Arrowhead team will discuss its proprietary pulmonary Targeted RNAi Molecule (TRiM) platform and the therapeutic potential of the Company’s investigational RNAi candidates, ARO-MUC5AC and ARO-RAGE, in these disease areas.
- ARO-MUC5AC is designed to reduce production of mucin 5AC (MUC5AC) as a potential treatment for various muco-obstructive pulmonary diseases.
- ARO-RAGE is designed to reduce production of the receptor for advanced glycation end products (RAGE) as a potential treatment for various inflammatory pulmonary diseases.
A live question and answer session will follow.